<?xml version="1.0" encoding="UTF-8"?>
<results title="human">
 <result pre="p&gt; physical mapping of the canine genome, linkage mapping and cloning with characterization of the " exact="RPGR" post=" gene, led to the identification of the causative RPGR variants in different dog breeds and " xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre=" cloning with characterization of the RPGR gene, led to the identification of the causative " exact="RPGR" post=" variants in different dog breeds and finally to gene therapy. &lt;a href=&quot;#i2164-2591-7-5-8-b03" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="nitis pigmentosa (RP) with tapetal-like reflexes and patchy retinal atrophy. Missense mutations in " exact="PRPS1" post=" can have multiple effects, causing Arts Syndrome, X-linked Charcot-Marie Tooth 5, and X-linked non" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="and X-linked nonsyndromic deafness. The absence of affected males in the RP families suggests some " exact="PRPS1" post=" variants may be embryonic male lethal when inherited in the hemizygous state. In another family co" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="-b05&quot;&gt;5 was possible through targeted genomic NGS that revealed a deep intronic mutation in " exact="OFD1" post=". 6 Point mutations in the coding region and splice si" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre=" 6 Point mutations in the coding region and splice sites of " exact="OFD1" post=" cause ciliopathies, including male-lethal orofaciodigital syndrome 1, Simpson-Golabi-Behmel syndro" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre=" mutations and can also result in combinations of polymorphic variants in exon 3. Mutations in the " exact="OPN1LW" post=" (LW) and OPN1MW (MW) cone opsin genes can lead to a wide array of cone photoreceptor abnorm" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre=" result in combinations of polymorphic variants in exon 3. Mutations in the OPN1LW (LW) and " exact="OPN1MW" post=" (MW) cone opsin genes can lead to a wide array of cone photoreceptor abnormalities, including prog" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="onal read-through (TR-T) drugs, can be used in therapy. An example is the case of mutations in the " exact="RP2" post=" gene, which leads to vision loss in a form of X-linked RP, and is often affected by nonsense mutat" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="ctive measures can also be designed and tested. Three-dimensional optic cups from iPSCs carrying a " exact="CEP290" post=" mutation that causes LCA revealed that the optic cups have higher levels of aberrant splicing caus" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="&quot;#i2164-2591-7-5-8-b09&quot;&gt;9 leading to a 5-fold increase in the correctly spliced mRNA in the " exact="CEP290" post="-LCA optic cups. Thus, personalized models, such as these optic cups as well as advanced molecular " xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="08 demonstrated therapeutic proof-of-concept for treatment of human retinal degenerations. For the " exact="RPE65" post="-LCA trial, the vector is delivered by a subretinal surgical approach, which treats a delimited are" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="a synaptic disease. Adeno-associated virus (AAV)-RS1 gene therapy in XLRS retinoschisis knockout ( " exact="RSI" post="-KO) mice closes the schisis cavities seen in XLRS patients, improves synaptic function, and increa" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
 <result pre="Following the lead of the LCA clinical trials for mutations of the " exact="RPE65" post=" gene, there are currently a number of gene therapy clinical trials in progress on different forms " xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="rgardt disease, and Usher syndrome, with preclinical work on many disease-causing genes, including " exact="PDE6" post=" and RPGR. Nowhere is this more important than in therapy for cones of the macula, because t" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
 <result pre="and Usher syndrome, with preclinical work on many disease-causing genes, including PDE6 and " exact="RPGR" post=". Nowhere is this more important than in therapy for cones of the macula, because these photorecept" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="The mode of action of the " exact="NXNL1" post=" gene product is complex, involving stimulation of glucose metabolism by RdDVF and repair of oxidat" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="be lost in one retinal region but retained in the remaining regions. A mutation in the rhodopsin ( " exact="RHO" post=") gene was the earliest report of a cause for RP, specifically, adRP. Over the years though, this c" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="he years though, this complexity has increased from one mutation to more than 100 mutations in the " exact="RHO" post=" gene. The question then became &quot;Was there any way to make sense of the phenotypes of this large nu" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="he question then became &quot;Was there any way to make sense of the phenotypes of this large number of " exact="RHO" post=" genotypes?&quot; In the 1990s, many investigators cataloged the subjective onset of night blindness and" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre=" night blindness and the degree of rod dysfunction and patterns of field loss in subjects carrying " exact="RHO" post=" mutations. In 1998, we divided the RHO diseases into two main phenotypic classes with accom" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="tion and patterns of field loss in subjects carrying RHO mutations. In 1998, we divided the " exact="RHO" post=" diseases into two main phenotypic classes with accompanying genotyping. &lt;a href=&quot;#i2164-2591" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="ypic classes with accompanying genotyping. 31 Class A " exact="RHO" post=" mutants have severe, early rod-cell loss with residual cone function following normal cone density" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="y. Genotypes include, for example, R135G, R135L, R135W, E181K, V345L, and P347L mutations. Class B " exact="RHO" post=" mutants exhibit slow loss of rod function in certain retinal regions; cone function can remain nor" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="More recently, we examined a large cohort of " exact="RHO" post=" Class B patients clinically, and with psychophysics and imaging (cross sectional and en face) at d" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="typing and phenotyping, attention can now turn to some very practical questions about treatment of " exact="RHO" post=" mutations, specifically therapy of Class B RHO mutants with remaining rod vision and struct" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre=" very practical questions about treatment of RHO mutations, specifically therapy of Class B " exact="RHO" post=" mutants with remaining rod vision and structure. For a local (subretinal) therapy, is it best at a" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="There is a three-component pattern of visual loss in Class B " exact="RHO" post=" patients. " xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="iest treatment delivery approach but, with what we now know, this would be ill advised for Class B " exact="RHO" post=" patients. " xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre=" Abstract: Mutations in the rhodopsin ( " exact="RHO" post=") gene are the most common cause of autosomal dominant retinitis pigmentosa (adRP) and no treatment" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre=" silent mutations. This combined gene therapy approach was tested in dogs that carry a mutation in " exact="RHO" post=" and show similar features of disease as reported in Class B RHO-adRP patients. Our results show su" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="Mutations in the rhodopsin ( " exact="RHO" post=") gene are a common cause of autosomal-dominant retinitis pigmentosa (adRP) and constitute 30% to 4" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="te 30% to 40% of this type of retinal degeneration (1/40,000). Over 150 different mutations in the " exact="RHO" post=" gene are known to be responsible for adRP. Many of these result in a toxic gain of function mechan" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="oduction of rhodopsin, both the wild-type (WT) and mutant alleles, and then replace them with a WT " exact="RHO" post=" cDNA that has been modified to be resistant to the knockdown tool (e.g., shRNA) and results in the" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre=" mastiff in which a form of retinal degeneration caused by a point mutation, Thr4Arg (T4R), in the " exact="RHO" post=" gene are the only naturally occurring animal models of RHO adRP identified to this date. &lt;s" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre=" mutation, Thr4Arg (T4R), in the RHO gene are the only naturally occurring animal models of " exact="RHO" post=" adRP identified to this date. 49 The phenotype, chara" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="marily the central retina, closely mimics the altitudinal distribution of disease reported in some " exact="RHO" post="-adRP patients. Besides its large (human-sized) eye and the presence of a central bouquet of cone p" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="nerations, 50 a significant value of the heterozygote " exact="RHO" post="-adRP dog model is that it expresses natural levels of both mutant and WT RHO protein. This is extr" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="ies 52 with light sensitivity especially prominent in " exact="RHO" post=" mutants, experimentally produced or naturally occurring, and ranging from Xenopus laevis to mouse," xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="g. The possible deleterious effect of environmental light exposure has also been suggested in some " exact="RHO" post="-adRP patients with an altitudinal pattern of disease. 53 &lt;/s" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="e avoidance course to test both rod- and cone-mediated vision failed to show any impairment in T4R " exact="RHO" post=" mutant dogs exposed to the highest dose of light damage. Retention of far peripheral rods, and cen" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre=" at the University of Florida (Hauswirth, Lewin) was set up to develop and test a gene therapy for " exact="RHO" post="-adRP. As a strategy that could provide a treatment for all RHO mutations irrespective of th" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre=" and test a gene therapy for RHO-adRP. As a strategy that could provide a treatment for all " exact="RHO" post=" mutations irrespective of their mechanism of action, the investigators opted to develop an allele-" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre=" the following: (1) inhibition of the expression of both the normal (WT) and the mutant alleles of " exact="RHO" post=", and (2) replacement of endogenous RHO expression with a copy of the normal RHO gene" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="on of both the normal (WT) and the mutant alleles of RHO, and (2) replacement of endogenous " exact="RHO" post=" expression with a copy of the normal RHO gene, which is made resistant to siRNA or ribosome" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="s of RHO, and (2) replacement of endogenous RHO expression with a copy of the normal " exact="RHO" post=" gene, which is made resistant to siRNA or ribosome degradation through silent mutations. After scr" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="lly reduced expression of endogenous RHO levels (both at the RNA and protein levels) in WT and T4R " exact="RHO" post=" mutant dogs was identified. Following validation of this lead shRNA 820, a resistant hu" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="and RHO 820 (scAAV2/5-HOP-RHO 820-H1-shRNA 820) was tested in T4R " exact="RHO" post=" mutant dogs. Subretinal injection (titer: 5 Ã— 10 11 vector genomes/mL) under infrared i" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="The RHO dog is a large animal model that recapitulates features of Class B " exact="RHO" post=" mutations seen in the human. " xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="ceptor cells. To develop therapies for eventual translation to the clinic, we have used the canine " exact="NPHP5" post=" ( IQCB1) model where a C-terminal truncation causes a photoreceptor ciliopathy with early o" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
 <result pre="o develop therapies for eventual translation to the clinic, we have used the canine NPHP5 ( " exact="IQCB1" post=") model where a C-terminal truncation causes a photoreceptor ciliopathy with early onset and rapid " xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre=" done in canine models, and subsequently in mouse disease models. Best disease and now, LCA due to " exact="NPHP5" post=" mutations, have been described in the dog. These pathologies have the same general features as in " xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
 <result pre="Defects in the " exact="NPHP5" post=" ( IQCB1) gene are known to cause an early onset, severe form of retinal degeneration within" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
 <result pre="Defects in the NPHP5 ( " exact="IQCB1" post=") gene are known to cause an early onset, severe form of retinal degeneration within the LCA group " xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="to cause an early onset, severe form of retinal degeneration within the LCA group of dystrophies ( " exact="NPHP5" post="-LCA). The disease is a ciliopathy in which defects are present in the photoreceptor connecting cil" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
 <result pre="ne for passing soluble and membrane components from inner segments to outer segments. Mutations in " exact="NPHP5" post=" are also found in Senior Loken Syndrome (SLSN) in which there is cystic kidney disease (nephronoph" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
 <result pre="stic kidney disease (nephronophthisis, NPHP) as well as LCA. Ciliopathies, such as those caused by " exact="CEP290" post=" and RPGR mutations, have been extensively reviewed and a framework has been proposed to inv" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="e (nephronophthisis, NPHP) as well as LCA. Ciliopathies, such as those caused by CEP290 and " exact="RPGR" post=" mutations, have been extensively reviewed and a framework has been proposed to investigate aspects" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" name="human"/>
 <result pre="tinal ciliopathy in the Pit Bull Terrier caused by a single nucleotide insertion in exon 10 of the " exact="NPHP5" post=" gene. This causes a premature stop that truncates the C-terminus of the native protein. Clinically" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
 <result pre="und to parallel and recapitulate that seen in clinical testing of human patients. This includes an " exact="NPHP5" post=" mutation with early loss of rods but relative retention of central retinal cone photoreceptors cel" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
 <result pre="With this knowledge, the dog " exact="NPHP5" post="-LCA model appeared to be suitable for preclinical studies on gene replacement therapy. To begin th" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
 <result pre=" leading to a &quot;shorter procedure time and milder postoperative conjunctival swelling.&quot; In the LCA- " exact="NPHP5" post=" dog, we injected the NPHP5 transgene, using AAV5, scAAV8 Y733F vectors with inte" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
 <result pre="ime and milder postoperative conjunctival swelling.&quot; In the LCA- NPHP5 dog, we injected the " exact="NPHP5" post=" transgene, using AAV5, scAAV8 Y733F vectors with interphotoreceptor retinoid-binding pr" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
 <result pre="&quot;#i2164-2591-7-5-8-b61&quot;&gt;61 have previously demonstrated from studies in human patients that " exact="NPHP5" post="-LCA is an excellent candidate for &quot;cone-directed gene augmentation therapy&quot; ( &lt;a href=&quot;#i2164-2591" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
 <result pre="rod ERGs as well as functional vision measured up to 1.3 years after treatment (Aguirre GD, et al. " exact="IOVS" post=" 2016;57:ARVO E-Abstract 2293). This therapy allowed for retention of a significant number of photo" xpath="/html[1]/body[1]/div[2]/div[7]/div[3]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
 <result pre="An " exact="NPHP5" post=" exon 10 insertion in dogs results in an early-onset, aggressive LCA-ciliopathy, similar to that se" dictionary="hgnc" dictionaryCheck="false" name="human"/>
</results>
